CRT-123 A Novel Nano Particle Sirolimus Delivery Via Coated Balloon  by Sojitra, Prakash et al.
a blinded analysis. The images were analyzed by image analysis software. The density and
area of the pixels was proportionate to the amount of the clot formed on the graft surface.
Results: The pressure gradient between the groups was identical throughout the study,
meaning similar flow characteristics were maintained in all branches. The pretreated grafts
had fewer blood clots adhered to the surface by direct visual inspection. The image analysis
showed 5 vs.39 clots, 0.01% vs. 1.8% clotted area and 62 vs. 5630 clot pixel area between
the treated and non-treated grafts respectively, p 0.05.
Conclusion: Pretreatment of the synthetic graft with heparin prior to implantation
reduces the risk of early clot formation. This simple practice might be helpful to prevent
initial thrombosis of the graft and later occlusion especially in critical situations where the
patency of the graft is crucial.
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Objectives: Objective of this study was to develop non-polymeric sirolimus nanoparticle
coated balloon and demonstrate in-tissue transfer through DCB in rabbit model.
Background: Drug coated balloon (DCB) is an emerging technology. To date paclitaxel
is a choice in DCB. Due to lipophilic properties of sirolimus, short time delivery through
DCB is a major challenge. To overcome current limitations, we hypothesized; nanopar-
ticle sirolimus coated on the balloon can provide better delivery and retention.
Methods: We prepared phospholipid encapsulated sirolimus and coated on the balloon
with novel coating formulation. The characteristics of the nanoparticle sirolimus DCB
was tested in both an in-vitro and preclinical in-vivo models. New Zealand rabbits
underwent drug coated balloon dilatation in iliac arteries for pharmacokinetics, confocal
microscopy and scanning electronic microscopy studies.
Results: Sirolimus nanoparticles were	400nm with stable solution. Coating surface was
smooth without defect and irregularities. In-tissue uptake of sirolimus was at 1, 7 and 14
days with concentration of 140.6, 15.5 and 5.5 ng/mg, respectively. Sirolimus coated
balloon with 3x inflations was also safe in the rabbit iliac arteries. Confocal microscopy
showed homogeneous fluorescent tagged nano sirolimus (DTF-nSRL) distribution into
the artery wall with intima to adventitia flow. None of the in-vivo investigation has
reflected emboli in downward stream.
Conclusion: Present set of experiments showed adequate amount of sirolimus was
delivered through non-polymeric DCB. Multiple inflation demonstrated safety to
co-relate with actual clinical outcome. Confocal imaging has showed homogenous
distribution in cross section and longitude parts. Path of drug travel was to the deepen area
of arterial wall upon time from intima to adventitia (Table 1).
Table 1. Depth of DTF-nSRL signal punctuation in rabbit iliac arteries
Time Point 24 hour 3 day 7 day
Depth of penetration 10-20m 10-30m 10-40m
Drug Eluting Stents
CRT-124
Comparative In Vitro Effects Of Paclitaxel, Everolimus, And Tacrolimus On
Macrophage-derived Foam Cells, Smooth Muscle Cells, And Endothelial Cells
Steven Hsu, Eugen Koren, Yen Chan, Mirna Koscec, Debby Feder
Abbott Vascular, Santa Clara, CA
Background: Macrophage-derived foam cells (FC) play a key role in atherosclerotic
lesion progression. Effects of different drugs used in drug-eluting stents (DES) on FC
behavior have not been well characterized. We used an in vitro model to compare effects
of paclitaxel, everolimus, and tacrolimus on FC, human coronary endothelial cell
(HCAEC), and human coronary smooth muscle cell (HCASMC) viability, FC gene
expression, and FC inflammatory cytokine levels.
Methods: FC were derived from human THP1 macrophages with acetylated LDL,
followed by treatment with paclitaxel, everolimus, or tacrolimus (10-5-10-11M) for 24 hrs
(n4). HCAEC and HCASMC were similarly treated with all three drugs. Cell lysates
and media supernatants were analyzed for apoptosis/necrosis using a Cell Death
Detection ELISAPLUS (Roche, Pleasanton, CA) assay. FC lysates were also evaluated
for apoptosis (survivin, clusterin) and autophagy (MAP1LC3) gene expression via a
Quantigene® Plex assay (Affymetrix, Santa Clara, CA). FC supernatants were analyzed
for MCP1 levels via a Procarta® mmunoassay (Affymetrix). Statistical significance was set
at p0.05 by ANOVA/Holm’s t-test.
Results: FC apoptosis was significantly increased compared to control at 10-5M for both
everolimus and paclitaxel, with no effects on FC necrosis for both drugs. Tacrolimus did
not affect FC apoptosis or necrosis. Paclitaxel (10-5M) significantly increased clusterin and
decreased survivin expression in FC. Tacrolimus did not affect gene expression while
everolimus (10-5M) significantly increased MAP1LC3 and clusterin (p0.10) and
decreased survivin expression in FC. Everolimus (10-5M) significantly decreased MCP1
in FC supernatants. Effects of all three drugs on HCASMC and HCAEC viability were
also explored. While everolimus and tacrolimus did not affect apoptosis or necrosis,
paclitaxel (10-5M) significantly increased HCASMC and HCAEC apoptosis and
necrosis.
Conclusion: The three drugs explored in this study have variable effects on FC,
HCASMC, and HCAEC. Unlike paclitaxel and tacrolimus, everolimus may inhibit FC
accumulation in atheromas through selective autophagy/apoptosis of FC and inhibition of
monocyte recruitment into the arterial wall.
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Background: Diffuse coronary lesions are often treated with long and overlapping
drug-eluting stents (DES) creating a full metal jacket, however the impact on clinical
outcomes comparing different generation DES has not been described.
Methods: We conducted a retrospective analysis of 98 patients with full metal jacket
stenting, defined as the total and continuous stent length of  50 mm in a single vessel,
treated using either first-generation (sirolimus- and paclitaxel-eluting) DES or second-
generation (everolimus-eluting) DES.
Results: Full metal jacket stenting was performed in 36 patients/71 lesions with
second-generation DES (Xience V or Promus); and 62 patients/151 lesions with
first-generation DES (Cypher or Taxus). Baseline characteristics were similar between the
groups. More second-generation DES were used per patient than first-generation DES
(3.2 vs. 2.6, p0.001); mean stent length (23.9 vs. 25.3mm) and diameter (2.9mm in
both) were similar (pNS). Angiographic success was 100% in both groups. At 1-year
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